Compare FVRR & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | XFOR |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | Israel | United States |
| Employees | N/A | 143 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.4M | 407.5M |
| IPO Year | 2019 | N/A |
| Metric | FVRR | XFOR |
|---|---|---|
| Price | $10.85 | $4.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $18.43 | $9.00 |
| AVG Volume (30 Days) | ★ 877.5K | 362.3K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.67 | $1.35 |
| 52 Week High | $34.13 | $4.83 |
| Indicator | FVRR | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 48.34 |
| Support Level | $9.97 | $3.97 |
| Resistance Level | $11.33 | $4.09 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 32.46 | 44.23 |
Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.